publication date: Jun. 28, 2019

Clinical Roundup CheckMate-459 results for Opdivo don’t meet OS endpoint in hepatocellular carcinoma

Bristol-Myers Squibb Co. announced topline results from CheckMate-459, randomized phase III study evaluating Opdivo (nivolumab) vs. sorafenib as a first-line treatment in patients with unresectable hepatocellular carcinoma.

The trial did not achieve statistical significance for its primary endpoint of overall survival per the pre-specified analysis (HR=0.85 [95% CI: 0.72-1.02]; p=0.0752). No new safety signals were observed with Opdivo. The full study results will be presented at an upcoming medical meeting, the company said.

While CheckMate-459 did not reach its pre-specified primary endpoint, the results showed a clear trend towards improvement in OS for patients treated with Opdivo, compared to sorafenib, a current standard of care, the company said.

CheckMate-459 was a phase III randomized, multi-center study evaluating Opdivo versus sorafenib as a first-line treatment in patients with unresectable hepatocellular carcinoma. Patients were treated until disease progression or unacceptable toxicity.

The primary endpoint of the trial was overall survival. Secondary endpoints included overall response rate, progression-free survival, and the relationship between tumor PD-L1 expression and efficacy.

Opdivo is being studied by the company across multiple settings and lines of therapy for HCC, including as monotherapy in the adjuvant setting (CheckMate-9DX [NCT03383458]) and in combination with Yervoy (ipilimumab) for previously treated patients … Continue reading CheckMate-459 results for Opdivo don’t meet OS endpoint in hepatocellular carcinoma

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.